Fintel reports that on December 17, 2024, Oppenheimer initiated coverage of Inari Medical (NasdaqGS:NARI) with a Outperform recommendation.
Analyst Price Forecast Suggests 16.57% Upside
As of December 3, 2024, the average one-year price target for Inari Medical is $66.15/share. The forecasts range from a low of $50.50 to a high of $90.30. The average price target represents an increase of 16.57% from its latest reported closing price of $56.75 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Inari Medical is 544MM, a decrease of 5.24%. The projected annual non-GAAP EPS is 0.22.
What is the Fund Sentiment?
There are 561 funds or institutions reporting positions in Inari Medical. This is an decrease of 62 owner(s) or 9.95% in the last quarter. Average portfolio weight of all funds dedicated to NARI is 0.31%, an increase of 3.54%. Total shares owned by institutions increased in the last three months by 7.28% to 72,476K shares. 
The put/call ratio of NARI is 0.18, indicating a bullish outlook.
What are Other Shareholders Doing?
IJR - iShares Core S&P Small-Cap ETF holds 3,185K shares representing 5.44% ownership of the company. In its prior filing, the firm reported owning 3,346K shares , representing a decrease of 5.06%. The firm decreased its portfolio allocation in NARI by 26.84% over the last quarter.
HCC Manager holds 2,914K shares representing 4.98% ownership of the company. No change in the last quarter.
Alliancebernstein holds 2,147K shares representing 3.67% ownership of the company. In its prior filing, the firm reported owning 2,412K shares , representing a decrease of 12.35%. The firm decreased its portfolio allocation in NARI by 0.14% over the last quarter.
Brown Advisory holds 1,826K shares representing 3.12% ownership of the company. In its prior filing, the firm reported owning 1,811K shares , representing an increase of 0.81%. The firm decreased its portfolio allocation in NARI by 65.28% over the last quarter.
Armistice Capital holds 1,822K shares representing 3.11% ownership of the company. In its prior filing, the firm reported owning 1,009K shares , representing an increase of 44.61%. The firm increased its portfolio allocation in NARI by 96.54% over the last quarter.
Inari Medical Background Information
(This description is provided by the company.)
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
